Condition (MeSH)
Hyperprolactinemia
ClinicalTrials.gov lists 39 trials for Hyperprolactinemia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
39 of the 39 trials are tagged with Hyperprolactinemia itself; the rest are tagged with a narrower condition beneath it.
When did Hyperprolactinemia trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperprolactinemia trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 7 |
| Not applicable | 3 |
| Observational | 18 |
How many Hyperprolactinemia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 21 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperprolactinemia trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Changchun GeneScience Pharmaceutical Co., Ltd. | 2 |
| Pfizer | 2 |
| Genovate Biotechnology Co., Ltd., | 1 |
Which drugs are being tested for Hyperprolactinemia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Aripiprazole | 5 |
| GnRH | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cabergoline Pill | 4 |
| Kisspeptin 112-121 | 2 |
| risperidone or paliperidone | 1 |
| Cabergoline tablets reference formulation | 1 |
| amantadine HCl ER | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Hyperprolactinemia? (58)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. | The Journal of clinical endocrinology and metabolism | 2024 | Yes |
| Prolactin in headache and migraine: A systematic review of clinical studies. | Cephalalgia : an international journal of headache | 2023 | Yes |
| <sup>11</sup>C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. | Pituitary | 2022 | Yes |
| Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review. | Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC | 2020 | Yes |
| Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. | Progress in neuro-psychopharmacology & biological psychiatry | 2020 | Yes |
Showing 5 of 58 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.